Search Result

Results for "

IDH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Isocitrate Dehydrogenase (IDH) (65) Apoptosis (7) Bacterial (2) Biochemical Assay Reagents (1) DAPK (1) Drug Intermediate (1) Drug Metabolite (1) Fungal (2) Isotope-Labeled Compounds (1) NAMPT (1) Nuclear Hormone Receptor 4A/NR4A (1) PDK-1 (1) PERK (1) Reactive Oxygen Species (ROS) (2) Reference Standards (6) Small Interfering RNA (siRNA) (13) TMV (1) Virus Protease (2)
By Research Areas:	Cancer (59) Infection (1) Inflammation/Immunology (2) Metabolic Disease (3) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (4) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (5) siRNAs (13)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Isocitrate Dehydrogenase (IDH)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-104042

Vorasidenib 5+ Cited Publications AG-881	Isocitrate Dehydrogenase (IDH)	Cancer
Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC₅₀ ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation .

HY-18690

Enasidenib 15+ Cited Publications AG-221	Isocitrate Dehydrogenase (IDH)	Cancer
Enasidenib is an oral, potent, reversible, selective inhibitor of the *IDH2* mutant enzymes, with IC₅₀s of 100 and 400 nM against IDH2 ^R140Q and IDH2 ^R172K, respectively.

HY-N0328

alpha-Mangostin 5+ Cited Publications α-Mangostin	Reactive Oxygen Species (ROS) Apoptosis Bacterial Fungal Virus Protease	Cancer
alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a K_i of 2.85 μM.

HY-114226

Olutasidenib 3 Publications Verification FT-2102	Isocitrate Dehydrogenase (IDH)	Inflammation/Immunology Cancer
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC₅₀ values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .

HY-15734

AGI-6780 5+ Cited Publications	Isocitrate Dehydrogenase (IDH)	Cancer
AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2 ^R140Q with IC₅₀ of 23±1.7 nM. AGI-6780 is less potent against IDH2 ^WT with IC₅₀ of 190±8.1 nM.

HY-104036

IDH-305 4 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
IDH-305 is an orally available, mutant-selective and brain-penetrant *IDH1* inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC₅₀= 27 nM (IDH1 ^R132H), 28 nM (IDH1 ^R132C), 6.14 µM (IDH1 ^WT)) .

HY-18082

AGI-5198 Maximum Cited Publications 20 Publications Verification IDH-C35	Isocitrate Dehydrogenase (IDH)	Cancer
AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 ^R132H inhibitor with an IC₅₀ of 0.07 μM.

HY-18690A

Enasidenib mesylate 15+ Cited Publications AG-221 mesylate	Isocitrate Dehydrogenase (IDH)	Cancer
Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the *IDH2* mutant enzymes.

HY-18948

GSK321 1 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
GSK321 is a potent, selective mutant *IDH1* inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .

HY-129545

DS-1001b 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
DS-1001b is an orally active, blood-brain permeable, potent *IDH-1* (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity .

HY-100020

BAY-1436032 3 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

HY-12475

*Mutant IDH1-IN-1* 2 Publications Verification Agios 135	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-1 (Agios 135) is a selective mutant *IDH1* inhibitor with activity against both IDH1 ^R132H and IDH1 ^R132C. Mutant IDH1-IN-1 reduces the level of 2-hydroxyglutarate (2-HG), stabilizes mutant IDH1 protein, and restores blocked monocyte differentiation. Mutant IDH1-IN-1 can be used in tumor-related research .

HY-128661

IDH1 Inhibitor 2 4 Publications Verification	Isocitrate Dehydrogenase (IDH)	Metabolic Disease
IDH1 Inhibitor 2 (compound 13) is a potent wild-type *IDH1* inhibitor that exerts its activity through covalent modification of His315 with an IC₅₀ value of 110 nM. IDH1 Inhibitor 2 can dose-dependently reduce the intracellular reduced glutamine metabolic flux, thereby affecting cellular metabolic homeostasis. IDH1 Inhibitor 2 can be used to study the role of IDH1 in cellular metabolic regulation and cancer development .

HY-145594

Safusidenib 2 Publications Verification AB-291; DS-1001	Isocitrate Dehydrogenase (IDH)	Cancer
Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant *IDH1* inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma . Safusidenib exhibits activity against *IDH1R132H, and IDH1R132C* with IC₅₀s of 15, and 130 nM in assays without any preincubation, respectively .

HY-18767A

(R,S)-Ivosidenib (R,S)-AG-120	Isocitrate Dehydrogenase (IDH)	Inflammation/Immunology Cancer
(R,S)-Ivosidenib ((R,S)-AG-120) is a (R,S)-enantiomer of Ivosidenib (AG-120) with lower activity. Ivosidenib can be used in research on IDH1-mutant cancers .

HY-19540

GSK864 5+ Cited Publications	Isocitrate Dehydrogenase (IDH)	Cancer
GSK864, a chemical probe, is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC₅₀ values of 8.8, 15.2 and 16.6 nM.

HY-112056

DIM-C-pPhCO2Me 1 Publications Verification	Nuclear Hormone Receptor 4A/NR4A Apoptosis DAPK Isocitrate Dehydrogenase (IDH) PERK	Cancer
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and *IDH1, induces markers of ER stress (CHOP, ATF4* and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .

HY-128888

(R,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(R,R)-GSK321 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC₅₀ value of 120 nM. (R,R)-GSK321 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity .

HY-13972

*Mutant IDH1 inhibitor* 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC₅₀ of < 72 nM.

HY-41648

IDH1 Inhibitor 8	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 *(IDH1)* inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer .

HY-N0328R

alpha-Mangostin (Standard) 5+ Cited Publications α-Mangostin (Standard)	Fungal Reactive Oxygen Species (ROS) Bacterial Apoptosis Virus Protease Reference Standards	Cancer
alpha-Mangostin (Standard) is the analytical standard of alpha-Mangostin. This product is intended for research and analytical applications. alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a K_i of 2.85 μM.

HY-W017463

trans-3-(3-Pyridyl)acrylic acid	Drug Intermediate TMV Isocitrate Dehydrogenase (IDH)	Infection
trans-3-(3-Pyridyl) acrylic acid is an unsaturated carboxylic acid and synthetic building block, which serves as a synthetic precursor of 3-(3-pyridyl) propanoic acid. trans-3-(3-Pyridyl) acrylic acid can be used to prepare dual mutant *IDH1/NAMPT* inhibitors and PGE₂ antagonist analogs. In addition, trans-3-(3-Pyridyl) acrylic acid exhibits antiviral activity against tobacco mosaic virus (TMV) .

HY-131312

Crelosidenib LY3410738; Mutant IDH1-IN-6	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC₅₀s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes .

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-GSK321 is the (S,R)-enantiomer of GSK321 (HY-18948). GSK321 is a potent, selective mutant *IDH1* inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .

HY-112289

IDH889	Isocitrate Dehydrogenase (IDH)	Cancer
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 ^R132H, IDH1 ^R132C and IDH1 ^wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM .

HY-18717

*Mutant IDH1-IN-2* 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.

HY-112601

IDH1 Inhibitor 1	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant *IDH1* inhibitor with IC₅₀s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1 ^R132H, IDH1 ^R132C, and IDH1 ^WT, respectively . Anticancer activity .

HY-P2993

Isocitrate dehydrogenase, Porcine heart ICDH; IDH	Isocitrate Dehydrogenase (IDH)	Metabolic Disease Cancer
Isocitrate dehydrogenase, Porcine heart (ICDH) is a citric acid or tricarboxylic acid cycle enzyme, is often used in biochemical studies. Isocitrate dehydrogenase catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduces NAD(P) ⁺ to NAD(P)H, it plays important roles in cellular metabolism .

HY-RS06527

IDH1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IDH1 Human Pre-designed siRNA Set A contains three designed siRNAs for IDH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IDH1 Human Pre-designed siRNA Set A IDH1 Human Pre-designed siRNA Set A

HY-RS06528

Idh1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Idh1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Idh1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Idh1 Mouse Pre-designed siRNA Set A Idh1 Mouse Pre-designed siRNA Set A

HY-RS06531

Idh2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Idh2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Idh2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Idh2 Mouse Pre-designed siRNA Set A Idh2 Mouse Pre-designed siRNA Set A

HY-RS06533

IDH3A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IDH3A Human Pre-designed siRNA Set A contains three designed siRNAs for IDH3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IDH3A Human Pre-designed siRNA Set A IDH3A Human Pre-designed siRNA Set A

HY-110144

TC-E 5008	Isocitrate Dehydrogenase (IDH)	Cancer
TC-E 5008 is a potent mutant IDH1 inhibitor with K_i values of 190 nM and 120 nM for R132H and R132C IDH1 mutants, respectively. TC-E 5008 exhibits very weak activity against WT-IDH1 with a K_i value of 12.3 μM. TC-E 5008 has anti-proliferative activity on multiple ER positive breast cancer cell lines .

HY-19208

ZD-2767P	Isocitrate Dehydrogenase (IDH)	Others
ZD-2767P (Compound 1) is a reversible and competitive inhibitor of *IDH1, with its IC₅₀* value being 410 nM .

HY-159833

Ranosidenib	Isocitrate Dehydrogenase (IDH)	Cancer
Ranosidenib is a isocitrate dehydrogenase (IDH) inhibitor with antitumor activity .

HY-149359

*IHMT-IDH1-053*	Isocitrate Dehydrogenase (IDH)	Cancer
IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible *IDH1-mutant* inhibitor with an IC₅₀ of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC₅₀=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants .

HY-175213

*Mutant IDH1-IN-7*	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-7 is a highly selective Isocitrate Dehydrogenase 1 (IDH1) R132H (IC₅₀ = 0.26 μM, K_d = 2.1 μM)/R132C (IC₅₀ = 1.1 μM) inhibitor. Mutant IDH1-IN-7 has no inhibitory effect on wild-type IDH1, IDH2-wt, and IDH2 R140Q. Mutant IDH1-IN-7 inhibits 2-Hydroxyglutarate (2-HG) production in U87-MG R132H cells (EC₅₀ = 0.55 μM). Mutant IDH1-IN-7 exhibits moderate antiproliferative effects on U87-MG R132H and HT-1080 cells .

HY-114459

*Mutant IDH1-IN-4*	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-4 (compound 434) is an inhibitor of *mutant Isocitrate dehydrogenase 1 (IDH* 1), with IC₅₀** values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells .

HY-186102

IDH1 ligand 1	Isocitrate Dehydrogenase (IDH)	Others
IDH1 ligand 1 (Compound 18) can serve as a negative control for the IDH1 target, with no detectable affinity for wild-type IDH1 and an IC₅₀ >10,000 nM .

HY-131312A

Crelosidenib gentisate LY3410738 gentisate; Mutant IDH1-IN-6 gentisate	Isocitrate Dehydrogenase (IDH)	Cancer
Crelosidenib (gentisate) is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC₅₀ of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Crelosidenib (gentisate) is less active at inhibiting the IDH wild-type enzymes .

HY-120765

BRD2879	Isocitrate Dehydrogenase (IDH)	Cancer
BRD2879 is a potent *IDH1-R132H* inhibitor with IC₅₀ values of 0.05, 2.5, >20, >20 µM for IDH1-R132H, IDH1-R132C, IDH1-WT, IDH2-R140Q, respectively. BRD2879 reduces (R)-2-hydroxyglutarate (R-2HG) levels .

HY-18690R

Enasidenib (Standard) AG-221 (Standard)	Isocitrate Dehydrogenase (IDH) Reference Standards	Cancer
Enasidenib (Standard) is the analytical standard of Enasidenib. This product is intended for research and analytical applications. Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.

HY-RS06530

IDH2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IDH2 Human Pre-designed siRNA Set A contains three designed siRNAs for IDH2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IDH2 Human Pre-designed siRNA Set A IDH2 Human Pre-designed siRNA Set A

HY-124698

MRK-A	Isocitrate Dehydrogenase (IDH)	Cancer
MRK-A is a selective, blood-brain-barrier permeable mutant IDH1 inhibitor with an IC₅₀ value of 5 nM. MRK-A inhibits 2-HG production. MRK-A has anti-cancer activity against brain tumors .

HY-174978

SK60	Isocitrate Dehydrogenase (IDH)	Others
SK60 is a dimethylated derivative of GSK321 (HY-18948) with low nanomolar potency and high selectivity for *IDH1R132H* (IC₅₀ = 14.5 nM). SK60 can be used as a tracer for brain imaging with the fluorescent label [ ¹⁸F] .

HY-100476

*Mutant IDH1-IN-3*	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-3 (Compound 1) is a selective allosteric inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). Mutant IDH1-IN-3 has an IC₅₀ of 13 nM for R132H IDH1. Mutant IDH1-IN-3 inhibits the production of D-2-hydroxyglutaric acid (2HG) in cells. Mutant IDH1-IN-3 can be used in the study of cancer .

HY-136686

IDH-C227	Isocitrate Dehydrogenase (IDH)	Cancer
IDH-C227 is a potent and selective IDH1 ^R132H inhibitor. IDH-C227 has anticancer effcts .

HY-112289B

*(1R)-IDH889*	Isocitrate Dehydrogenase (IDH)	Cancer
(1R)-IDH889 is the isomer of IDH889 (HY-112289), and can be used as an experimental control. IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 ^R132H, IDH1 ^R132C and IDH1 ^wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM .

HY-162772

IDH1/2-IN-1	Isocitrate Dehydrogenase (IDH) Apoptosis	Cancer
IDH1/2-IN-1 (Compound 6b) serves as a dual inhibitor of *IDH1(R132H)/IDH2(R140Q)* with IC₅₀ values of 0.22 μM and 1.6 μM, respectively. IDH1/2-IN-1 effectively inhibits tumor growth by suppressing tumor cell proliferation and enhancing host defense through the activation of antioxidant enzymes. Additionally, IDH1/2-IN-1 reduces inflammation and promotes apoptosis, demonstrating robust antitumor activity. IDH1/2-IN-1 holds potential for research in leukemia .

HY-158319

*Mutant IDH1/NAMPT-IN-1*	Apoptosis Isocitrate Dehydrogenase (IDH) NAMPT	Cancer
Mutant IDH1/NAMPT-IN-1 (Compound 23h) is a dual inhibitor of mutant isocitrate dehydrogenase 1 (mutant IDH1) (IC₅₀=14.93 nM) and nicotinamide phosphoribosyltransferase (NAMPT) (IC₅₀=12.56 nM). Mutant IDH1/NAMPT-IN-1 can induce apoptosis. Mutant IDH1/NAMPT-IN-1 crosses the blood-brain barrier effectively .

Cat. No.	Product Name

HY-L092

Glucose Metabolism Compound Library

1,652 compounds

Glucose homeostasis is tightly regulated to meet the energy requirements of the vital organs and maintain an individual’s health. Glucose metabolism includes glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, oxidative phosphorylation and other metabolic pathways. Glucose is the major carbon source that provides the main energy for life. Glucose metabolism dysregulation is also implicated in many diseases such as diabetes, heart disease, neurodegenerative diseases and even cancer.

MCE offers a unique collection of 1,652 compounds related to glucose metabolism, which target glucose metabolism related targets, such as GLUT, Hexokinase, Pyruvate Kinase, IDH, etc. MCE glucose metabolism library is a powerful tool for studying glucose metabolism and drug discovery of diseases related to glucose metabolism.

HY-L064

Glutamine Metabolism Compound Library

1,690 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0328

alpha-Mangostin 5+ Cited Publications α-Mangostin	other families Xanthones Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Cancer	Reactive Oxygen Species (ROS) Apoptosis Bacterial Fungal Virus Protease
alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a K_i of 2.85 μM.

HY-N0328R

alpha-Mangostin (Standard) 5+ Cited Publications α-Mangostin (Standard)	Structural Classification other families Xanthones Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Fungal Reactive Oxygen Species (ROS) Bacterial Apoptosis Virus Protease Reference Standards
alpha-Mangostin (Standard) is the analytical standard of alpha-Mangostin. This product is intended for research and analytical applications. alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a K_i of 2.85 μM.

HY-N12390

Alternaphenol B2	Microorganisms Phenols Polyphenols Source Classification	Isocitrate Dehydrogenase (IDH)
Alternaphenol B2 is a selective *IDH1* inhibitor from the coral-derived fungus Parengyodontium album SCSIO SX7W11. Alternaphenol B2 shows inhibitory activity against isocitrate dehydrogenase mutant R132H (IDH1m), with IC₅₀ values of 41.9 μM .

Species:	Virus (1) Human (5)
Tag:	His (4)
Source:	HEK293 (2) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70214A

	IDH1 Protein, Human (HEK293, His) rHuIsocitrate dehydrogenase [NADP] cytoplasmic/IDH1, His; Isocitrate Dehydrogenase [NADP] Cytoplasmic; IDH; Cytosolic NADP-Isocitrate Dehydrogenase; IDP; NADP(+)-Specific ICDH; Oxalosuccinate Decarboxylase; IDH1; PICD	Human	HEK293
	The IDH1 protein catalyzes the oxidative decarboxylation of isocitrate to generate 2-oxoglutarate, which is utilized by enzymes such as phytoacyl-CoA dioxygenase. IDH1 Protein, Human (HEK293, His) is the recombinant human-derived IDH1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70214

	IDH1 Protein, Human (HEK293, His, Solution) rHuIsocitrate dehydrogenase [NADP] cytoplasmic/IDH1, His; Isocitrate Dehydrogenase [NADP] Cytoplasmic; IDH; Cytosolic NADP-Isocitrate Dehydrogenase; IDP; NADP(+)-Specific ICDH; Oxalosuccinate Decarboxylase; IDH1; PICD	Human	HEK293
	The IDH1 protein catalyzes the oxidative decarboxylation of isocitrate to generate 2-oxoglutarate, which is utilized by enzymes such as phytoacyl-CoA dioxygenase. IDH1 Protein, Human (HEK293, His, Solution) is the recombinant human-derived IDH1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P704085

	IDH1 Protein, Human (R132H, His) rHuIsocitrate dehydrogenase NADP cytoplasmic/IDH1, His; Isocitrate Dehydrogenase NADP Cytoplasmic; IDH; Cytosolic NADP-Isocitrate Dehydrogenase; IDP; NADP(+)-Specific ICDH; Oxalosuccinate Decarboxylase; IDH1; PICD	Human	E. coli
	The IDH1 protein catalyzes the oxidative decarboxylation of isocitrate to generate 2-oxoglutarate, which is utilized by enzymes such as phytoacyl-CoA dioxygenase. IDH1 Protein, Human (R132H, His) is the recombinant human-derived IDH1 protein, expressed by E. coli, with C-8*His labeled tag.

HY-P704669

	IDH1 Protein, Human (R132C, His) rHuIsocitrate dehydrogenase NADP cytoplasmic/IDH1, His; Isocitrate Dehydrogenase NADP Cytoplasmic; IDH; Cytosolic NADP-Isocitrate Dehydrogenase; IDP; NADP(+)-Specific ICDH; Oxalosuccinate Decarboxylase; IDH1; PICD	Human	E. coli
	The IDH1 protein catalyzes the oxidative decarboxylation of isocitrate to generate 2-oxoglutarate, which is utilized by enzymes such as phytoacyl-CoA dioxygenase. IDH1 Protein, Human (R132C, His) is the recombinant human-derived IDH1 protein, expressed by E. coli, with C-His labeled tag.

HY-P704086

	IDH1 Protein, Human (His) rHuIsocitrate dehydrogenase [NADP] cytoplasmic/IDH1, His; Isocitrate Dehydrogenase [NADP] Cytoplasmic; IDH; Cytosolic NADP-Isocitrate Dehydrogenase; IDP; NADP(+)-Specific ICDH; Oxalosuccinate Decarboxylase; IDH1; PICD	Human	E. coli
	The IDH1 protein catalyzes the oxidative decarboxylation of isocitrate to generate 2-oxoglutarate, which is utilized by enzymes such as phytoacyl-CoA dioxygenase. IDH1 Protein, Human (His) is the recombinant human-derived IDH1 protein, expressed by E. coli, with C-8*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-150238S

IDH1 Inhibitor 7-d2
IDH1 Inhibitor 7-d₂ is the deuterium labeled IDH1 Inhibitor 7 (HY-150238). IDH1 Inhibitor 7 is an *IDH1* inhibitor with an IC₅₀ of less than 100 nM .

HY-18690S

Enasidenib-d6
Enasidenib-d₆ (AG-221-d₆) is the deuterium labeled Enasidenib (HY-18690) . Enasidenib is an oral, potent, reversible, selective inhibitor of the *IDH2* mutant enzymes, with IC₅₀s of 100 and 400 nM against IDH2 ^R140Q and IDH2 ^R172K, respectively .

Host:	Mouse (6) Rabbit (2)
Reactivity:	Human (8) Rat (4) Mouse (5) Monkey (2)
Application:	IHC-P (3) ICC/IF (4) IP (1) WB (4) FC (6) ELISA (4)
Isotype:	IgG (2) IgG1 (6)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84351

	IDH2 Antibody (YA4048) IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH	IHC-P, FC, ELISA	Human
	IDH2 Antibody (YA4048) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IDH2.

HY-P84351A

	IDH2 Antibody (YA4048)(PBS only) IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH	IHC-P, FC, ELISA	Human
	IDH2 Antibody (YA4048) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IDH2.

HY-P83868

	IDH1 Antibody (YA3565) IDH; IDP; IDCD; IDPC; PICD; HEL-216; HEL-S-26	WB, ICC/IF, FC, ELISA	Human, Mouse, Monkey
	IDH1 Antibody (YA3565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IDH1.

HY-P83868A

	IDH1 Antibody (YA3565)(PBS only) IDH; IDP; IDCD; IDPC; PICD; HEL-216; HEL-S-26	WB, ICC/IF, FC, ELISA	Human, Mouse, Monkey
	IDH1 Antibody (YA3565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IDH1.

HY-P83320

	IDH2 Antibody (YA3065) IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH	WB	Human, Rat
	IDH2 Antibody (YA3065) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IDH2.

HY-P80995

	IDH1 Antibody (YA3516) 1 Publications Verification	WB, IHC-P, IP	Human, Mouse, Rat
	IDH1 Antibody (YA3516) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IDH1.

HY-P88358

	IDH3A Antibody (YA8042) H-IDH alpha; isocitrate dehydrogenase (NAD+) alpha chain; isocitrate dehydrogenase 3 (NAD+) a; isocitrate dehydrogenase [NAD] subunit alpha; isocitric dehydrogenase; mitochondrial; NAD(H)-specific isocitrate dehydrogenase alpha subunit; NAD+-specific ICDH	ICC/IF, FC	Human, Mouse, Rat
	IDH3A Antibody (YA8042) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IDH3A.

HY-P88358A

	IDH3A Antibody (YA8042)(PBS only) H-IDH alpha; isocitrate dehydrogenase (NAD+) alpha chain; isocitrate dehydrogenase 3 (NAD+) a; isocitrate dehydrogenase [NAD] subunit alpha; isocitric dehydrogenase; mitochondrial; NAD(H)-specific isocitrate dehydrogenase alpha subunit; NAD+-specific ICDH	ICC/IF, FC	Human, Mouse, Rat
	IDH3A Antibody (YA8042) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IDH3A.